Pharma Bro Shkreli asks judge to find no wrongdoing in Daraprim lawsuit [Reuters]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Reuters
REUTERS/Carlo Allegri WASHINGTON (Reuters) - Jailed “Pharma Bro” Martin Shkreli, his former company Vyera Pharmaceuticals and others asked a judge Monday to find that the company broke no laws in its handling of the drug Daraprim, which saw its price increase by more than 4,000% in one day. The Federal Trade Commission filed a lawsuit in January 2020, alleging that the company that Shkreli once ran protected its dominance of the drug by restricting distribution to ensure generic drug makers could not get the samples needed to bring out a cheaper version of the drug. The company, formerly Turing Pharmaceuticals, also prevented potential competitors from buying an ingredient, the FTC said. Daraprim, which is used to treat toxoplasmosis, saw its price go from $17.50 per tablet to $750. Toxoplasmosis is a common parasitic infection that rarely causes serious problems, unless the infected person has a weakened immune system. In a filing on Monday, the defendants said that the FTC h
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalGlobeNewswire
- OUTbio San Diego Celebrates First Anniversary: A Year of Empowerment and Inclusion for LGBTQ+ Life Science Professionals in San Diego [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 2/15/24 - Beat
TVTX
Sec Filings
- 4/12/24 - Form 4
- 3/27/24 - Form ARS
- 3/27/24 - Form DEFA14A
- TVTX's page on the SEC website